- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01367522
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
November 26, 2019 updated by: Bausch Health Americas, Inc.
A Phase 1, Open-Label, Study to Evaluate Single Dose Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Volunteers With Impaired Hepatic Function
This is a multicenter, non-randomized, single-dose, parallel-group study.
Each subject will receive a subcutaneous dose of MNTX.
Eight subjects with normal hepatic function and eight subjects from each classification of hepatic impairment will be enrolled.
Plasma samples will be collected before and at specified intervals after dosing and the concentration of MNTX will be analyzed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Tarrytown, New York, United States, 10591
- Progenics Pharmaceuticals, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females between the ages of 18-80 years
- Body weight greater than 100 lbs and BMI between 18-38
- Liver values that are abnormal must not be clinically relevant as judged by the investigator. Liver enzyme and bilirubin must be less than 5 times the upper normal of reference range and may be repeated under fed conditions if abnormal. Stable hepatitis patients as well as cirrhosis patients of either etiology.
Exclusion Criteria:
- History of current alcohol abuse with less than 1 year abstinence
- Conditions possibly affecting drug absorption, e.g. gastrectomy or clinically significant diabetic gastroenteropathy.
- Currently pregnant or nursing
- Methadone use.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Concentration of SC MNTX
Time Frame: 20 days
|
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
|
20 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of Maximum Plasma Concentration of SC MNTX
Time Frame: 20 days
|
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
|
20 days
|
Area Under the Plasma Concentration versus Time Curve (AUC) of SC MNTX
Time Frame: 20 days
|
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
|
20 days
|
Percentage of SC MNTX Excreted in Urine
Time Frame: 20 days
|
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
|
20 days
|
Urinary Clearance of SC MNTX
Time Frame: 20 days
|
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
|
20 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Primary Completion (Actual)
July 1, 2004
Study Completion (Actual)
July 1, 2004
Study Registration Dates
First Submitted
May 27, 2011
First Submitted That Met QC Criteria
June 6, 2011
First Posted (Estimate)
June 7, 2011
Study Record Updates
Last Update Posted (Actual)
November 27, 2019
Last Update Submitted That Met QC Criteria
November 26, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MNTX 1107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Dysfunction
-
Loma Linda UniversityWithdrawnLiver Graft Dysfunction
-
National Cancer Institute (NCI)Completed
-
University of AthensCompleted
-
Taipei City HospitalNational Yang Ming UniversityCompletedLiver DysfunctionTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chong Kun Dang PharmaceuticalCompletedLiver DysfunctionKorea, Republic of
-
University of AlbertaRecruitingLiver DysfunctionUnited States, Australia, Canada, Poland, United Kingdom
-
Zhejiang Medicine Co., Ltd.Huashan HospitalCompleted
-
PfizerCompletedMild Hepatic Dysfunction | Moderate Hepatic DysfunctionSouth Africa
-
Institutul Clinic FundeniCompleted
Clinical Trials on SC Methylnaltrexone (MNTX)
-
Bausch Health Americas, Inc.CompletedHealthy SubjectsUnited States
-
University Medicine GreifswaldCompleted
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedRenal ImpairmentUnited States
-
Bausch Health Americas, Inc.CompletedHealthy Male VolunteersUnited States
-
Bausch Health Americas, Inc.Wyeth is now a wholly owned subsidiary of PfizerCompletedAdvance Illness Patients With OICUnited States
-
Bausch Health Americas, Inc.CompletedNormal VolunteersUnited States
-
Bausch Health Americas, Inc.CompletedPostoperative IleusUnited States